GlassScriptPhysician profile
Julian A Bragg
NPI 1164606018
$21,079.11
in general payments reported to CMS, 2019-2025
79 companies · $4,161 in 2025
The $4,161 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $2,360 · 2021: $2,575 · 2022: $2,739 · 2023: $3,439 · 2024: $3,554 · 2025: $4,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,070.04 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,751.92 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Ucb, INC. | $1,399.44 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $1,138.62 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Teva Pharmaceuticals USA, INC. | $756.96 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $597.98 | 2019-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $570.86 | 2020-2025 | |
| Lilly USA, LLC | $544.06 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Pfizer INC. | $537.09 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $498.18 | 2021-2025 | Onpattro, Amvuttra |
| Novartis Pharmaceuticals Corporation | $471.90 | 2019-2024 | |
| Neurelis, INC. | $465.46 | 2021-2025 | Valtoco |
| Amgen INC. | $464.45 | 2019-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $464.18 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Mdd US Operations, LLC | $447.63 | 2019-2025 | Gocovri, Gocovri |
| Otsuka America Pharmaceutical, INC. | $429.70 | 2023-2025 | Rexulti, Nuedexta |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Bragg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.